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Abstract 
Background:  The prevalence of epilepsy is high in Madagascar (23.5/1000), as is the treatment gap (estimated at 
92 %). The health system of the country is underfunded; some AEDs are used, and the national drug policy does not 
encourage price regulation or the administration of generic agents. We conducted a cross‑sectional study to assess 
the availability and cost of solid oral AED formulations in Antananarivo, capital of Madagascar. Data were gathered 
from all officially registered pharmacies (according to the drug agency list, updated in 2015) by means of telephone 
interviews lasting no more than 10 min and conducted by a native Malagasy speaker. With regard to other sources 
(hospitals, illicit sales) data were obtained at specific visits. The study received ethical approval from the Madagascar 
Ministry of Health.
Findings:  A total of 91 of 100 pharmacies (the nine not included were because of an inoperative phone number), 
two of three public hospitals, and two illegal outlets were investigated. Sodium valproate was available in 84.6 % 
of the pharmacies, while carbamazepine and phenobarbital were available in 68.1 % and 36.3 % of the pharmacies, 
respectively, but phenytoin was not available in any supply chain. There were more originator brands than generic for‑
mulations, with a higher cost (range 20.3–81.1 %, median 40.7 %) compared to the equivalent generic. The public sys‑
tem had only a very limited choice of AED, but offered the lowest costs. Illicit sources were more expensive by 54.3 % 
for carbamazepine and 62.5 % for phenobarbital. Concerning the annual cost of treatment, the average percentage 
of the gross national income per capita based on the purchasing power parity was 29.8 %/19.0 % (brand/generic) for 
sodium valproate, 16.4 %/7.3 % (brand/generic) for carbamazepine, 8.9 %/5.1 % (brand/generic) for phenobarbital.
Conclusions: The main sources of AEDs were private pharmacies, but the stocks held were low. The financial burden 
was still important in the capital of Madagascar, mainly the consequence of a highly developed private sector at the 
expense of the public sector. Although sodium valproate remains the most expensive solution, it still remains the 
most available instead of phenobarbital. The most striking feature of this study concerns the cost of AEDs in the infor‑
mal sector, mostly used because they are deemed to provide less costly drugs, the opposite was observed there. The 
assessment of the cost and availability of medicines was easily and quickly implemented. It provided a relevant focus 
of the situation in areas difficult to investigate, in terms of road network and geographical situation.
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Background
Epilepsy is a chronic neurological disease affecting more 
than 70 million people worldwide (Ngugi et  al. 2010). 
Among them, nearly 90  % live in resource-limited set-
tings where problems of accessibility, affordability and 
availability of antiepileptic drugs are dramatic. In those 
areas, the treatment gap (proportion of people with epi-
lepsy who require treatment but do not receive it) has 
been established to be over 75  % (Meyer et  al. 2010). 
Primary healthcare is extremely limited in developing 
countries, where only a small proportion of major and 
first-line antiepileptic drugs (AEDs) are commonly used: 
phenobarbital, carbamazepine, sodium valproate, phe-
nytoin. The burden is even more dramatic in rural areas 
where in addition to a low availability the sustainability 
of drugs supply is often not guaranteed (Perucca 2007). 
This situation could also be seen in developed European 
countries where the median availability of all type of 
AEDs (older and newer) is 82 % ranging from 48 to 100 % 
(Baftiu and Johannessen 2015). Madagascar is not spared, 
with a high prevalence of epilepsy (23.5/1000) (Ba-Diop 
et al. 2014). The treatment gap has been estimated to 92 % 
by an indirect method (based on the drug consumption 
over the year) and at 32 % by a direct method (based on 
how many of the detected cases are not receiving treat-
ment in a prevalence study) (Meyer et al. 2010; Ratsim-
bazafy et  al. 2011; Kale 2002). The health system of the 
country is underfunded; some antiepileptic drugs (AEDs) 
are used, but the national drug policy does not encourage 
price regulation or the administration of generic agents. 
The total health expenditure in Madagascar was 3.04 % of 
the Grow Domestic Product which was in 2015 and per 
capita around 1439 current international $, adjusted on 
the purchasing power parity (World Bank data, 2014). 
Against this background, we conducted a cross-sectional 
study to assess the availability and cost of solid oral AED 
formulations in Antananarivo, capital of Madagascar, 
which had a population of 2.2 million in 2014.
Methods
This study was performed as an ancillary study of a pro-
ject aiming at assessing the quality of solid oral AEDs 
formulations in sub-Saharan Africa, in twelve countries 
and in all kind of supply chain (official and illegal one). 
Information on availability and cost was gathered from 
all officially registered pharmacies (according to the drug 
agency list, updated in July 2015) by means of telephone 
interviews lasting no more than 10  min and conducted 
by a native Malagasy speaker. With regard to other type 
of supply chain (hospitals, illicit sales) data were obtained 
at specific visits. The study received ethical approval from 
the Madagascar Ministry of Health.
Results
A total of 91 of 100 pharmacies (the nine not included 
were because of a wrong/inoperative phone number), two 
of three public university hospitals, and two illegal out-
lets were investigated. Sodium valproate was available in 
84.6 % of the pharmacies, while carbamazepine and phe-
nobarbital were available in 68.1 and 36.3 % of the phar-
macies, respectively, but phenytoin was not available in 
any supply chain. Availability and costs by AED and dos-
age are detailed in Table  1. There were more originator 
brands than generic formulations (e.g. sodium valproate 
200 mg, 84.2 % for originator brand compare to 4.4 % of 
generic), with a higher cost (range 20.3–81.1 %; median 
40.7  %) compared to the equivalent generic. The public 
system had only a very limited choice of AED, but offered 
the lowest costs in the official system (10.0  % lower for 
sodium valproate, 36.4 % for carbamazepine and 43.7 % 
for phenobarbital). Illicit sources were more expensive 
by 54.3  % for carbamazepine and 62.5  % for phenobar-
bital; this trend was less marked for sodium valproate. 
All sources had only one or two boxes of each molecule 
available. Concerning the annual cost of treatment, the 
average percentage of the gross national income per cap-
ita based on the purchasing power parity (current inter-
national $) was 29.8/19  % (brand/generic) for sodium 
valproate, 16.4/7.3 % (brand/generic) for carbamazepine, 
8.9/5.1 % (brand/generic) for phenobarbital.
Discussion
The main sources of AEDs were private pharmacies. 
Three of the four major AEDs were available, but the 
stocks held were low. The financial burden for people 
with epilepsy was still important in the capital of Mada-
gascar. This was mainly the consequence of a very devel-
oped private sector at the expense of the public sector, 
without any price regulation. Originator brand remained 
more expensive than generic, ranging from 1.3 to 5.3 
higher. This result was less dramatic than data observed 
in a large survey conducted in 46 countries, where origi-
nator brand prices were about 30 times higher (Cameron 
et  al. 2012). Furthermore, although sodium valproate 
remains the most expensive solution, it still remains the 
most available instead of phenobarbital. However, the 
most striking feature of this study concerns the cost of 
AEDs in the informal sector: patients use these outlets 
mostly because they are deemed to provide less costly 
drugs, but the opposite was observed in Madagascar. 
This results must be confirmed by further investigations 
in other sites but the illicit supply chain is difficult to 
assess. Selling points are often not officially known, and 
these information are often obtained by word of mouth. 
The methodology to measure the cost and availability of 
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medicines by phone call, was easily and quickly imple-
mented. The main limit of this method is due to the 
cross-sectional assessment, that provide information in 
a given position at a given time, that could not be the 
real availability at any moment. Anyway, it can provide 
a relevant and a comprehensive focus of the situation in 
a very large and crowded area with many points to be 
investigated and with a heavily congested and practically 
unusable road network. This epidemiological assess-
ment provide data that could contribute to address the 
financial burden for people with epilepsy in the capital of 
Madagascar.
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